Qualitative and quantitative effects of APOE genetic variation on plasma C-reactive protein, LDL-cholesterol, and apoE protein

[1]  N. Cook,et al.  Association of Common CRP Gene Variants with CRP Levels and Cardiovascular Events , 2005, Annals of human genetics.

[2]  N. Cook,et al.  Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. , 2005, JAMA.

[3]  J. Manson,et al.  Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. , 2005, JAMA.

[4]  C. Carlson,et al.  Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. , 2005, American journal of human genetics.

[5]  P. Ridker,et al.  Tryptophanyl-tRNA synthetase gene polymorphisms and risk of incident myocardial infarction. , 2005, Atherosclerosis.

[6]  C. Sabin,et al.  Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Marian,et al.  Pharmacogenetic study of statin therapy and cholesterol reduction. , 2005, Current atherosclerosis reports.

[8]  W. März,et al.  The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the Ludwigshafen risk and cardiovascular health study). , 2004, European heart journal.

[9]  A. Windemuth,et al.  New and confirmatory evidence of an association between APOE genotype and baseline C-reactive protein in dyslipidemic individuals. , 2004, Atherosclerosis.

[10]  Meir J Stampfer,et al.  Meta-Analysis: Apolipoprotein E Genotypes and Risk for Coronary Heart Disease , 2004, Annals of Internal Medicine.

[11]  M. Austin,et al.  Heritability of C‐Reactive Protein and Association with Apolipoprotein E Genotypes in Japanese Americans , 2004, Annals of human genetics.

[12]  N. Cook,et al.  Clinical Usefulness of Very High and Very Low Levels of C-Reactive Protein Across the Full Range of Framingham Risk Scores , 2004, Circulation.

[13]  A. Hill,et al.  Common apolipoprotein E polymorphisms and risk of clinical malaria in the Gambia , 2004, Journal of Medical Genetics.

[14]  N. Cook,et al.  Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. , 2003, Human molecular genetics.

[15]  Peter Donnelly,et al.  A comparison of bayesian methods for haplotype reconstruction from population genotype data. , 2003, American journal of human genetics.

[16]  G. Kolovou,et al.  Apolipoprotein E Polymorphism and Atherosclerosis , 2003, Angiology.

[17]  Eric Boerwinkle,et al.  Contributions of 18 additional DNA sequence variations in the gene encoding apolipoprotein E to explaining variation in quantitative measures of lipid metabolism. , 2002, American journal of human genetics.

[18]  D. Schaid,et al.  Score tests for association between traits and haplotypes when linkage phase is ambiguous. , 2002, American journal of human genetics.

[19]  M. Krempf,et al.  Negative and independent influence of apolipoprotein E on C-reactive protein (CRP) concentration in obese adults. Potential anti-inflammatory role of apoE in vivo , 2001, International Journal of Obesity.

[20]  G. Siest,et al.  Genetic influences on lipid metabolism trait variability within the Stanislas Cohort. , 2001, Journal of lipid research.

[21]  N Rifai,et al.  Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. , 2001, JAMA.

[22]  C. Ehnholm,et al.  Apolipoprotein E polymorphism and C-reactive protein in dyslipidemic middle-aged men. , 2001, Atherosclerosis.

[23]  D. Levy,et al.  Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. , 2001, Atherosclerosis.

[24]  E. Boerwinkle,et al.  Sequence diversity and large-scale typing of SNPs in the human apolipoprotein E gene. , 2000, Genome research.

[25]  E. Boerwinkle,et al.  Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. , 2000, American journal of human genetics.

[26]  C. Sing,et al.  Influence of apolipoprotein E genotype variation on the means, variances, and correlations of plasma lipids and apolipoproteins in children , 1999, Annals of human genetics.

[27]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[28]  O. Faergeman,et al.  The apolipoprotein E polymorphism in Greenland Inuit in its global perspective , 1996, Human Genetics.

[29]  D. Rubinsztein,et al.  Arginine residues at codons 112 and 158 in the apolipoprotein E gene correspond to the ancestral state in humans. , 1995, Atherosclerosis.

[30]  A. M. Saunders,et al.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.

[31]  S. Gauthier,et al.  Apolipoprotein E polymorphism and Alzheimer's disease , 1993, The Lancet.

[32]  M. Pericak-Vance,et al.  Apolipoprotein E ∈4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases , 1993, The Lancet.

[33]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[34]  M. Pericak-Vance,et al.  Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage. , 1991, American journal of human genetics.

[35]  C. Sing,et al.  Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. , 1985, American journal of human genetics.

[36]  C. Hennekens,et al.  A randomized trial of aspirin and β-carotene among U.S. physicians , 1985 .

[37]  G. Utermann,et al.  Polymorphism of apolipoprotein E , 1979, Clinical genetics.

[38]  G. Utermann,et al.  Polymorphism of apolipoprotein E , 1978, Clinical genetics.

[39]  Mark B Pepys,et al.  C-reactive protein: a critical update. , 2003, The Journal of clinical investigation.

[40]  A. Rabinstein.  A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women , 2006 .

[41]  P. Ridker,et al.  C-reactive protein comes of age , 2005, Nature Clinical Practice Cardiovascular Medicine.

[42]  J. Manson,et al.  Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer The Women ’ s Health Study : A Randomized Controlled Trial , 2005 .

[43]  Ose,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .

[44]  R. Mahley,et al.  Apolipoprotein E: far more than a lipid transport protein. , 2000, Annual review of genomics and human genetics.

[45]  K. Weisgraber.  Apolipoprotein E: structure-function relationships. , 1994, Advances in protein chemistry.

[46]  E. Boerwinkle,et al.  Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. , 1988, American journal of human genetics.

[47]  C. Hennekens,et al.  A randomized trial of aspirin and beta-carotene among U.S. physicians. , 1985, Preventive medicine.